ReviewNature reviews. Gastroenterology & hepatology2016
Understanding the mechanisms of faecal microbiota transplantation.
Review in Nature reviews. Gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 325 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fecal Microbiota Transplantation in Newly Diagnosed Patients With Ulcerative Colitis - a Double Blind, Placebo-Controlled Trial
High Intensity, Multi-Donor, Oral Capsulized Fecal Microbiota Transplantation in Newly Diagnosed Pediatric Patients With Mild to Moderate Ulcerative Colitis - a Double Blind, Placebo-Controlled Trial
Faecal Microbiota Transplantation for Post-acute COVID-19 Syndrome: a Pilot Open-label Study
Disentangling Microbiome Engraftment by Multi-omics of the Gut Ecosystem During Fecal Transplant
Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics
Who cites it
325 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Effects of stoma discharge reinfusion on low anterior resection syndrome and the gut microbiota following sphincter-preserving surgery for middle and low rectal cancer: a randomized clinical trial.Updates in surgery · 2026Trial
- Encapsulated faecal microbiota transfer in young women with anorexia nervosa: an open-label feasibility pilot trial.Nature communications · 2025Trial
- Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrentGut microbes · 2025Trial
- Novel Microbial Engraftment Trajectories Following Microbiota Transplant Therapy in Ulcerative Colitis.Journal of Crohn's & colitis · 2025Trial
- ROS-triggerable dual nanocoated probiotics for inflammatory bowel disease treatment.Drug delivery · 2026Article
- Fecal Microbiota Transplantation BeyondJournal of Korean medical science · 2026Review
- Gram-Negative Bacterial Overgrowth Predominated by: Potential Association with Intestinal Barrier Impairment and Inflammatory Diarrhea in Cats.Veterinary sciences · 2026Article
- Associations Between Gut Microbiota and Tissue Exposure ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Microbiome and pancreatic ductal adenocarcinoma: mechanistic insights, microenvironmental interactions, and therapeutic implications.Molecular biology reports · 2026Review
- Microbiota-Mediator-Host Signaling Networks in Metabolic Syndrome: From Mechanistic Insights to Therapeutic Targeting.Microorganisms · 2026Review
- The Dual Role of the Gut Microbiota in Cancer Chemoresistance.MicrobiologyOpen · 2026Review
- Microbiome and aging: Trajectories of microbiome age across human ecosystems and their systemic effects.iMeta · 2026Review
- Safety of Fecal Microbiota Transplantation in Children: A Single-Center Experience.Children (Basel, Switzerland) · 2026Article
- Antiviral effect of lactoferrin against infectious bronchitis virus (IBV) are associated with alterations in the gastrointestinal microbiome.Poultry science · 2026Article
- A multi-strain biofilm consortium enhances gut microbiota resilience and restores post-antibiotic homeostasis.World journal of microbiology & biotechnology · 2026Article
- Validation of an Automated Fluorescence- and Image-Based Viable Cell Counting Method for Fecal Microbiota Transplantation Drug Products.Biotechnology journal · 2026Article
- The eternal struggle between titans: Fecal microbiota transplant (FMT) versus metformin in type 2 diabetes (T2D) gut dysmotility.Journal of advanced research · 2026Review
- The cancer-microbiome axis: Mechanisms and emerging therapeutic strategies.Seminars in immunopathology · 2026Review
265 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This Review summarizes mechanistic investigations in faecal microbiota transplantation (FMT), which has increasingly been adapted into clinical practice as treatment for Clostridium difficile infection (CDI) that cannot be eliminated with antibiotics alone. Administration of healthy donor faecal microbiota in this clinical situation results in its engraftment and restoration of normal gut microbial community structure and functionality. In this Review, we consider several main mechanisms for FMT effectiveness in treatment of CDI, including direct competition of C. difficile with commensal microbiota delivered by FMT, restoration of secondary bile acid metabolism in the colon and repair of the gut barrier by stimulation of the mucosal immune system. Some of these mechanistic insights suggest possibilities for developing novel, next-generation CDI therapeutics. FMT might also have potential applications for non-CDI indications. The gut can become a reservoir of other potential antibiotic-resistant pathogens under pressure of antibiotic treatments, and restoration of normal microbial community structure by FMT might be a promising approach to protect against infections with these pathogens as well. Finally, FMT could be considered for multiple chronic diseases that are associated with some form of dysbiosis. However, considerable research is needed to optimize the FMT protocols for such applications before their therapeutic promise can be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.